Document is current

Article History

Received: 9 September 2025

Accepted: 2 December 2025

First Online: 9 December 2025

Declarations

:

: Justyna Żubrowska received travel grants and lecture fees from MSD, Novartis, and AstraZeneca; and lecture fees from Pfizer, Swixx Biopharma, Gilead and Eli Lilly. Małgorzata Pieniążek received travel support and lecture fees from Pfizer and Novartis; lecture fees from Gilead; and participated in an advisory board for Novartis. Anna Polakiewicz-Gilowska received lecture honoraria and travel support from AstraZeneca, Roche, Novartis, Eli Lilly, Swixx Biopharma, Gilead, and Pfizer. Miro-slava Malejčíková served as a consultant and expert advisor for Novartis, Amgen, Pfizer, Roche, and AstraZeneca; received honoraria from Novartis, Pfizer, Roche, Teva, and AstraZeneca; and partici-pated in clinical studies sponsored by Novartis, Roche, AstraZeneca, and Pfizer. Miloš Holánek re-ceived travel and conference support from MSD, Gilead, Eli Lilly, and AstraZeneca; received lec-ture and speaker’s fees from Novartis, Gilead, Eli Lilly, and Teva; and served on advisory boards for AstraZeneca, Eli Lilly, and Gilead. Renáta Soumarová received honoraria and support from BMS, AstraZeneca, Pfizer, Novartis, Eli Lilly, MSD, Gilead, Janssen, Astellas, Servier, Accord, and GSK, including advisory board participation. Aleksandra Konieczna received travel grants and lecture fees from Pfizer, Novartis, Eli Lilly, MSD, AstraZeneca, and Gilead; and advisory board honoraria from Novartis. Iwona Danielewicz declares no conflicts of interest. Maja Lisik-Habib received honoraria for lectures from MSD, AstraZeneca, Johnson & Johnson, Roche, BMS, Astellas, Merck, and GSK. Aleksandra Łacko received honoraria and support from AstraZeneca, Pfizer, Novartis, Eli Lilly, Roche, and Gilead Sciences, including advisory board participation. Marcin Kubeczko served on advisory boards for Novartis; received speaker’s fees and conference support from Novartis, Roche, MSD, Pfizer, Eli Lilly, Teva, Amgen, Swixx Biopharma, AstraZeneca, and Gilead; and participated in clinical trials sponsored by Roche, MSD, Novartis, Seagen, and Gilead. Renata Pacholczak-Madej received travel grants from Accord and BMS; and lecture fees from AstraZeneca, BMS, MSD, GSK, Novartis, and Roche. Zuzana Bielčiková received travel grants and lecture honoraria from AstraZeneca, MSD, Roche, Novartis, Eli Lilly, and Gilead. Mirosława Püsküllüoğlu received travel grants and lecture honoraria from AstraZeneca, Roche, Novartis, Eli Lilly, Janssen, Gilead, and Amgen.